H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

JMP Securities reiterated a Market Outperform rating on Enanta Pharmaceuticals (NASDAQ:ENTA) shares with a consistent price target of $21.00. The firm's analysis highlighted the company's solid ...

Reports Q1 revenue $17M, consensus $17.25M. “2025 is primed to be a pivotal year for Enanta (ENTA) as we execute on multiple catalysts across ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Pfizer joins Minnesota and Company to discuss how to protect yourself by scheduling your vaccines to prevent serious consequences.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...